Alzheimer's disease (AD) is a chronic neurodegenerative disorder characterized by the
pathological accumulation of amyloid beta (Aβ) peptides and neurofibrillary tangles …

The blood vessels vascularizing the central nervous system exhibit a series of distinct
properties that tightly control the movement of ions, molecules, and cells between the blood …

Alzheimer's disease (AD) is a neurodegenerative disorder, marked by cortical and
hippocampal deposition of amyloid-β (Aβ) plaques and neurofibrillary tangles and cognitive …

Blood-brain barrier (BBB) separates the systemic circulation and the brain, regulating
transport of most molecules to protect the brain microenvironment. Multiple structural and …

Despite the enormity of the societal and health burdens caused by Alzheimer's disease
(AD), there have been no FDA approvals for new therapeutics for AD since 2003. This …

The evidence that neurovascular dysfunction is an integral part of Alzheimer's disease (AD)
pathogenesis has continued to emerge in the last decade. Changes in the brain vasculature …

Blood–brain barrier (BBB) breakdown can disrupt nutrient supply and waste removal, which
affects neuronal functioning. Currently, dynamic contrast-enhanced (DCE) MRI is the …

Therapies targeting late events in Alzheimer's disease (AD), including aggregation of
amyloid beta (Aβ) and hyperphosphorylated tau, have largely failed, probably because they …

To investigate whether blood–brain barrier (BBB) disruption is a potential mechanism of
usual age-related cognitive decline, we conducted dynamic contrast–enhanced (DCE) MRI …

Harmful materials in the blood are prevented from entering the healthy brain by a highly
selective blood–brain barrier (BBB), and impairment of barrier function has been associated …